Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 6/2021

01-06-2021 | Naloxone | Letter to the Editor

Acute motor effects induced by opioid antagonists in Parkinson’s disease: could naloxone be a rescue therapy?

Authors: Giuseppe Belfiore, Roberta Terranova, Giovanni Mostile, Donatella Contrafatto, Alessandra Nicoletti, Mario Zappia

Published in: Neurological Sciences | Issue 6/2021

Login to get access

Excerpt

Dear Editor, …
Appendix
Available only for authorised users
Literature
1.
Loh HH, Brase DA, Sampath-Khanna S, Mar JB, Way EL, Li CH (1976) Beta-endorphin in vitro inhibition of striatal dopamine release. Nature 264:567–568CrossRef
2.
Bloom F, Segal D, Ling N, Guillemin R (1976) Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194:630–632CrossRef
3.
Agnoli A, Ruggieri S, Falaschi P, Mearelli S, Del Roscio S, D'Urso R, Frajese G (1980) Are the enkephalins involved in Parkinson’s disease? Clinical and neuroendocrine response to naloxone administration. Adv Biochem Psychopharmacol 22:511–521PubMed
4.
Trabucchi M, Bassi S, Frattola L (1982) Effect of naloxone on the “on-off” syndrome in patients receiving long-term levodopa therapy. Arch Neurol 39:120–121CrossRef
5.
Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN (1978) Effect of an opiate antagonist on movement disorders. Arch Neurol 35:810–811CrossRef
6.
McEvoy GK (ed) Naloxone hydrochloride. In: AHFS Drug Information, Bethesda, pp 2236–2239
7.
Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J (2004) Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson’s disease. Mov Disord 19:554–560CrossRef
8.
Sgroi S, Tonini R (2018) Opioidergic modulation of striatal circuits, implications in Parkinson’s disease and levodopa induced dyskinesia. Front Neurol 9:524CrossRef
Metadata
Title
Acute motor effects induced by opioid antagonists in Parkinson’s disease: could naloxone be a rescue therapy?
Authors
Giuseppe Belfiore
Roberta Terranova
Giovanni Mostile
Donatella Contrafatto
Alessandra Nicoletti
Mario Zappia
Publication date
01-06-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 6/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04955-9

Other articles of this Issue 6/2021

Neurological Sciences 6/2021 Go to the issue

Original Article

Developmental venous anomalies in patients with multiple sclerosis: is that a coincidence or an ancillary finding?

Letter to the Editor

Authors’ reply to Bugiani O: More focus on SENECA with CAA

Original Article

Admission blood cell counts are predictive of stroke-associated infection in acute ischemic stroke patients treated with endovascular therapy

COVID-19

Testing olfactory dysfunction in acute and recovered COVID-19 patients: a single center study in Italy

Letter to the Editor

Statin use and Parkinson’s disease incidence

Correction

Correction to: The Italian validation of the communicative effectiveness index questionnaire: a multicentric study